Blog Coverage Eagle Pharma on a Biosimilar Development Initiative Sets to Acquire Arsia Therapeutics

Upcoming AWS Coverage on Zoetis Post-Earnings Results

LONDON, UK / ACCESSWIRE / November 14, 2016 / Active Wall St. blog coverage looks at the headline from Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) as the company announced on November 11, 2016, that it has entered into a definitive agreement to acquire the early-stage biotechnology firm, Arsia Therapeutics (“Arsia”), which is the developer of proprietary viscosity-reducing technology and formulation solutions. This acquisition primarily signals Eagle Pharma’s entry into biologics, one of the fastest growing sectors of the pharmaceuticals market. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

One of Eagle Pharma’s competitors within the Drugs – Generic space, Zoetis Inc. (NYSE: ZTS), reported on November 02, 2016, its financial results for the third quarter of 2016. AWS will be initiating a research report on Zoetis in the coming days.

Today, AWS is promoting its blog coverage on EGRX; touching on ZTS. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=EGRX

http://www.activewallst.com/registration-3/?symbol=ZTS

Bio-better Initiative

Eagle Pharmaceuticals is a pharmaceutical company which is known for development and commercialization of injectable products used to overcome the shortcomings or limitations of the existing and conventionally used injectable products.

With the Arsia Therapeutics’ acquisition, Eagle Pharma aims to bring a new portfolio into its fold where targeted biologics is the primary sector. With Arsia’s expertise, it aims to develop a new range of biosimilars and bio-betters.

While bio-betters are superior in one or more aspects than the reference product, the biosimilars are highly similar to the reference product and possess minor differences in clinically inactive components. This acquisition is set to strengthen Eagle Pharma’s formulation capabilities and expand its product portfolio. Although several pharmaceutical industries stake heavily on biosimilars, Eagle Pharma has probably viewed an elevating demand for bio-betters, and this acquisition may be considered as the first step to dominate the sector.

The Purchase amid Voluminous In-flow

The acquisition announcement will strengthen Eagle Pharma’s drive to stabilize its stocks. The global biosimilar market is estimated to touch the $20 billion mark by 2020. Hence, Eagle Pharma is banking on the bullish market through this collaboration with Arsia.

Arsia, on the other hand, is primarily a research firm aimed at delivering low-viscosity injectable solutions. On December 18, 2015, Arsia presented its latest formulation which helped administer high-dose monoclonal antibody therapies through low-volume subcutaneous injections and devices. Monoclonal antibodies normally require high dose levels of several mg/kg of body weight, which is not possible to administer through the conventional patient-friendly, subcutaneous rate. It was the exact spot where the low-viscosity solutions from Arsia would come to play.

Under terms of the agreement, Arsia’s founders will collaborate both as shareholders and researchers. Eagle Pharma will reportedly pay $30 million at the closure of the deal, of which $27.3 million will be paid in cash and the remaining $2.7 million will be delivered in Eagle Pharma’s common stock. Eagle Pharma has set certain milestones, upon which a release of an additional $48 million would be facilitated, thus adding up to a net aggregate of $78 million.

Stock Performance

Last Friday, the stock closed the trading session at $79.50, tumbling by 5.60% from its previous closing price of $84.22. A total volume of 698.06 thousand shares have exchanged hands, which was higher than the 3-month average volume of 459.11 thousand shares. Eagle Pharma’s stock price rallied 25.08% in the last month, 31.06% in the past three months, and 79.86% in the previous six months.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 448918